Dr Terence Friedlander closes his discussion by highlighting ongoing clinicals in neoadjuvant MIBC treatment that excite him and speculates on how he would use immunotherapy in patients with MIBC if it were available for use in both the neoadjuvant and adjuvant setting.
During a Targeted Oncology Case-Based Peer Perspective virtual event, Amir Mortazavi, MD andMoshe Ornstein, MD, MA discussed available treatment regimen for a patient with clear cell renal cell carcinoma and sarcomatoid features.
Closing out their program on HR+/HER2- metastatic breast cancer, panelists look toward future evolutions in the treatment landscape.
The approved PARP inhibitor niraparib has been beneficial for patients with recurrent ovarian cancer, but new second-line restrictions for certain patients have led physicians to be more cautious when re-challenging these patients.
Aristotelis Tsirigos, PhD, discusses a self-taught artificial intelligence tool being developed to accurately diagnose cases of adenocarcinoma.
The panel closes by summarizing recent advances in the field and shares hopes for future improvements in molecular testing and treatment options for patients with mNSCLC.
In this episode of Targeted Talks, Ben Derman, MD, dissects the latest advancements in myeloma treatment, focusing on the role of ClonoSeq and minimal residual disease monitoring.
Anthony Hunter, MD, discusses JAK inhibitor resistance and optimal strategies for treatment of patients with myelofibrosis.
John Strickler, MD, discusses targeting c-Met as a biomarker in gastric and gastroesophageal junction cancers.
Funda Meric-Bernstam, MD, discusses updated findings from the phase 1 TROPION-PanTumor01 study of datopotamab deruxtecan-dlnk in heavily pretreated locally advanced or metastatic urothelial cancer.
Expert perspectives on factors that aid in the selection of optimal therapy for patients with relapsed/refractory ALK+ non–small cell lung cancer.
Melissa Johnson, MD, discussed SHP2 inhibitors with Targeted Therapies in Oncology.
An olaparib triplet demonstrated efficacy in patients with recurrent advanced or metastatic endometrial cancer treated in the ENDOLA clinical trial.
Paolo Tarantino, MD, PhD, discusses elacestrant as a treatment option for patients with ESR1-mutated metastatic breast cancer in the second line.
The following list will provide you with suggestions for identifying the go-getters and how to include them in your practice or on your team.
Gizelka David-West, MD, analyzes the most compelling changes in up-front treatment and maintenance therapy for Ovarian Cancer Awareness Month.
Gayathri Ravi, MD, discusses the role minimal residual disease plays in decision making and treating patients with hematologic malignancies.
Arun Azad, MBBS, PhD, discusses ongoing studies of lutetium-177-PSMA radionuclide in patients with prostate cancer.
In the phase 2/3 REFRαME-O1 trial, luveltamab tazevibulin showed encouraging responses in patients with ovarian cancer with low to medium FRα expression.
Mohammed Milhem, MBBS discussed the mechanism of action of RP1, the design and preliminary findings of the IGNYTE trial in melanoma.
Mrinal M. Gounder, MD, delves into the data supporting the recent FDA approval of nirogacestat for the treatment of adult patients with desmoid tumors.
A key opinion leader on relapsed/refractory chronic lymphocytic leukemia provides practical advice on patient management and looks toward future evolutions in the treatment landscape.
Yannis K. Valtis, MD, provides background on a single-institution, retrospective cohort study which assessed laboratory and clinical tumor lysis syndrome in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma.
Brett Simon, MD, PhD, discusses an ongoing program at his institution that aims to improve symptoms and outcomes for patients with lung cancer who have undergone surgery.